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Reprogramming of energy metabolism is one of the emerging hallmarks of cancer. Up-regulation of energy
metabolism pathways fuels cell growth and division, a key characteristic of neoplastic disease, and can lead to
dependency on specific metabolic pathways. Thus, targeting energy metabolism pathways might offer the
opportunity for novel therapeutics. Here, we describe the application of a novel in vivo screening approach for the
identification of genes involved in cancer metabolism using a patient-derived pancreatic xenograft model.
Lentiviruses expressing short hairpin RNAs (shRNAs) targeting 12 different cell surface protein transporters were
separately transduced into the primary pancreatic tumor cells. Transduced cells were pooled and implanted into
mice. Tumors were harvested at different times, and the frequency of each shRNA was determined as a measure
of which ones prevented tumor growth. Several targets including carbonic anhydrase IX (CAIX), monocarboxylate
transporter 4, and anionic amino acid transporter light chain, xc- system (xCT) were identified in these studies and
shown to be required for tumor initiation and growth. Interestingly, CAIX was overexpressed in the tumor initiating
cell population. CAIX expression alone correlated with a highly tumorigenic subpopulation of cells. Furthermore,
CAIX expression was essential for tumor initiation because shRNA knockdown eliminated the ability of cells to
grow in vivo. To the best of our knowledge, this is the first parallel in vivo assessment of multiple novel oncology
target genes using a patient-derived pancreatic tumor model.
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Altered energy metabolism is a hallmark of cancer [1]. Important
metabolic genes have been found to be the direct targets of oncogenes
resulting in addiction to specific metabolic pathways [2]. For example,
while normal cells support energy production following glucose
deprivation by shifting to fatty acid oxidation, tumor cells expressing
constitutively activated AKT are addicted to glucose consumption and
are not viable under glucose-restricted conditions [3]. In addition to
glucose consumption, recent literature indicates an increased reliance of
tumor cells on specific amino transporters as well as pathways dedicated
to maintenance of pH homeostasis. Within these three areas of interest,
we have identified 12 genes implicated in providing tumors with the
necessary metabolic adaptations to allow the establishment of anabolic
processes and consequent tumor proliferation.
Our goal was to develop methods enabling a direct head-to-head
comparison of the requirement for these genes in tumor development.Such studies would be best carried out in vivo due to the likely
alterations of tumor metabolism imparted by microenvironment
factors such as hypoxia and competition/symbioses with the stromal
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develop transgenic mice and knockout mice containing germline
mutations in candidate oncogenes [4]. Generating these genetically
engineered mouse models is, however, time consuming and often
does not reflect human disease.
To accelerate the systematic analysis of cancer genes in vivo, scientists
have adapted loss of function screening by downregulating important
genes using the short hairpin RNA (shRNA) technology [5–8]. These
screens can be run in a pooled format in which numerous shRNAs can
be queried in parallel. The use of an established cell line in such studies
to validate the requirement for metabolic genes may yield misleading
results due to metabolic alterations introduced by adaptations to
prolonged growth in culture [9]. To avoid these and other potential
artifacts, patient-derived xenografts (PDXs) are increasingly being used
for in vivo studies [10]. We therefore used a pooled shRNA library
consisting of 12metabolism targets to assess the requirement for each of
these genes in the growth of a pancreatic PDXmodel (herein referred to
as PDX15) [11]. Of the 12 novel cell-surface metabolism targets, three
[carbonic anhydrase IX (CAIX), monocarboxylate transporter 4
(MCT4), and anionic amino acid transporter light chain, xc- system
(xCT)] were chosen to further validate the results of the shRNA screen.
Furthermore, we show that one of these targets, CAIX, is enriched in
tumor initiating cells (TICs) and required to initiate tumors in vivo.
To our knowledge, this is the first pooled shRNA screen using a
PDX model.Materials and Methods
Preparation of Single-Cell Suspensions of Tumor Cells
Tumors excised from animals were minced using sterile scalpel
blades. To obtain single-cell suspensions, the tumor pieces were
mixed with 200 units of ultrapure collagenase III (Worthington
Biochemicals, Freehold, NJ) per milliliter of Hank's balanced salt
solution (HBSS). The tumor suspension was incubated at 37°C for
approximately 1 hour, with mechanical disruption every 15 to 20
minutes by pipetting with a 5-ml pipette. At the end of the
incubation, cells were filtered through a 70-μm nylon mesh and
washed twice with HBSS.
Enrichment of Epithelial Cells
Epithelial cells from single-cell suspensions were obtained by using an
EasySep Human EpCAM Positive Selection Kit. Cells in the single-cell
suspension were targeted with Tetrameric Antibody Complexes
recognizing EpCAM and dextran-coated magnetic particles. Labeled
cells were separated using an EasySep magnet. Enriched cells were
washed once, and the cell number was counted on a Vi-cell.
Pooled shRNA Screening
pLKO.1 lentiviral particles encoding shRNAs against the different
targets were obtained from Sigma-Aldrich Corp (St Louis, MO), and a
library was assembled in the following way: The efficiency of
knockdown of different shRNAs for the respective targets (five shRNAs
per target) was evaluated, and the top two shRNAs were chosen for
library construction (representative data in Supplementary Figure 1).
Thus, we assembled a library of shRNAs composed of 27 shRNA
hairpins [24 shRNAs for 12 different targets, Aurora B shRNA
(positive control), Non Targeting (NT)-shRNA (negative control),
and Green fluorescent protein (GFP)-shRNA (negative control)].
Thereafter, EpCAM+ primary epithelial tumor cells were isolatedfrom PDX15 tumors and separately transduced with the 27 different
shRNAs in tissue culture flasks (Multiplicity of infection
(MOI) ~ 1). Forty-eight hours post-transduction, cells individually
transduced with respective shRNAs were harvested and combined
into a single pool (starting pool). Thereafter, 3 × 106 cells of the
starting pool (~1 × 105 cells/shRNA) were implanted into Recom-
bination Activating Gene 2 (RAG2) KOmice. The frequency of each
shRNA in the starting pool is described in Supplementary Table 1.
After 3 to 4 weeks, mice were sacrificed, and tumors were harvested.
Genomic DNA was isolated from the starting pool and tumors by
using the QIAamp DNA Mini Kit. To amplify the shRNAs
integrated into genomic DNA, polymerase chain reaction (PCR) was
performed for 30 cycles by using Accu Prime Kit (Invitrogen,
Waltham, MA), with 1 μg of total chromosomal DNA and the
primer pair described below. PCR products were purified and
quantitated by Quant-iT DNA Assay Kit (Invitrogen). All samples,
including the starting pool, were pooled at equal proportions and
analyzed by quantitative sequencing (Illumina, San Diego,CA).
Sequencing reads were deconvoluted using PERL software by
segregating the sequencing data by barcode andmatching the shRNA
stem sequences to those expected to be present in the shRNA pool,
allowing for mismatches of up to three nucleotides. The frequency of
each shRNA was compared between the starting pool and each
established tumor.
Primers for Amplifying shRNAs
The forward primer with Illumina adapter sequence is given as
follows: ACACTCTTTCCCTACACGACGCTCTTCCGATCT
TTTCGATTTCTTGGC.
The reverse primer with Illumina adapter sequence is given
as fol lows: CTCGGCATTCCTGCTGAACCGCTCTTCC
GATCTGATGAATACTGCCAT.
Statistical Analysis for shRNA Data Set
The data were log2 transformed before analysis. Independent
samples t tests were performed on the log2 transformed data using
Prism 6.03 where P b 0.05 was considered significant.
RNA Extraction and Quantitative PCR
Total RNA was isolated by using RNeasy Kit (Qiagen, Federick,
MD) according to the manufacturer’s protocol. To detect the
transcripts of interest, quantitative PCR (qPCR) was carried out using
One-Step Quantitative RT-PCR System (Life Technologies, Grand
Island, NY) with the respective TaqMan primer probes. Reactions
were performed using an ABI Prism 7900 Sequence Detector (Life
Technologies). All reactions were performed in triplicate. Results were
normalized to the housekeeping gene (18S). Relative gene expression
was calculated by using the 2−ΔΔCt method.
Fluorescence-Activated Cell Sorting
Dissociated cells (0.5 to 1 million) were plated in 100 μl of HBSS
onto a round-bottom, tissue culture–treated 96-well plate (BD
Falcon) and washed twice with HBSS containing 2% heat-inactivated
FBS [fluorescence-activated cell sorting (FACS) buffer] and resus-
pended in cold FACS buffer. Antibodies were added and incubated
for 20 minutes at 4°C. The sample was washed twice with cold FACS
buffer and resuspended in cold FACS buffer containing 4′,6-diami-
dino-2-phenylindole (1 μg/ml final concentration). The antibodies
used were anti–EpCAMPerCp-Cy5.5 purchased from eBioscience Inc
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isothiocyanate purchased from Life Technologies, anti–H2Kd-PE
purchased from BD Biosciences San Jose, CA), and anti–CAIX-PE
(R&D Systems, Minneapolis, MN). In all experiments using human
xenograft tissue, live cells were gated through the use of 4′,6-diami-
dino-2-phenylindole (Sigma-Aldrich Corp). Side scatter and forward
scatter profiles were used to eliminate cell doublets, and infiltrating
mouse cells were eliminated by gating on H2Kd (mouse histocom-
patibility class I) negative cells. TICs (EpCAM+CD44+CD24+) and
non-TICs (EpCAM+CD44−CD24−) were gated on epithelial cells
positive for EpCAM. Unstained samples were used to set gates, and
fluorescence minus one controls were used as compensation controls.
Sorting was done using FACSAria (BD Immunocytometry Systems,
Franklin Lakes, NJ). Cells were reanalyzed after sorting for purity,
which was typically N97%. To determine the percentage of TICs and
non-TICs in the tumors, the samples were analyzed using BD LSRII
flow cytometer (BD Biosciences), and the data were analyzed using
FlowJo software (TreeStar Inc, Ashland, OR).
In Vivo Studies
Human PDX15 xenografts were maintained as a serially passaged
xenograft model using female RAG2 KO mice (Taconic, Hudson,
NY). For in vivo tumorigenicity assays, sorted cells [EpCAM+CAIX
(high) or EpCAM+CAIX (low)] were washed with serum-free HBSS,
counted, and resuspended in a 1:1 HBSS and Matrigel mixture. Cells
(5000, 1000, 500, or 100) either EpCAM+CAIX (high) or
EpCAM+CAIX (low) were subcutaneously injected into the right
and left flanks, respectively, of the same mouse using a 23-gauge needle.
Mice were monitored weekly for tumor formation. Tumors were
harvested when they reached ~2000 mm3 in size.
All procedures were performed in accordance with institutional
guidelines in an Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC)-accredited facility and were
approved by the MedImmune, LLC Institutional Animal Care and
Use Committee.
Results
The 12 genes chosen to be included in the shRNA library encode
proteins that cover three critical areas of tumor metabolism implicated in
tumorigenesis. CAIX and CAXII, Sodium hydrogen exchanger 1
(NHE1), MCT1, MCT4, and CD147 all function in reversing the
intracellular acidification that occurs following reduction of pyruvate to
lactic acid during glycolysis [12–14]. Glut1 and sodium dependent
glucose co-transporter (SGLT1) are both glucose transporters upregulated
in tumors [13]. Finally, ASC amino-acid transporter 2 Sodium-Inde-
pendent (ASCT2), Neutral Amino Acid Transporter (LAT1), xCT, and
Zinc transporter (ZIP4) are transporters of nutrients required for tumor
growth [13,15,16]. Two shRNAs for each target, which showed N70%
silencing efficiency, were selected for assembling the custom library (see
Supplementary Figure 1 for representative data sets supporting selection
of LAT1 and Aurora B shRNAs). Overall, 24 different shRNAs covering
the 12 queried genes and one positive (Aurora B) and two negative
(non-targeting and GFP) shRNA controls were included in the custom
library. The shRNAs of the lentiviral-based shRNA library were separately
transduced into EpCAM-enriched (epithelial) primary pancreatic
(PDX15) tumor cells, and 48 hours post-transduction cells were
combined into a single pool. Cells (3 × 106) from the starting pool
were injected into RAG2 KO immunocompromised mice (Figure 1A).
Tumors were harvested at different times during tumor growth, andgenomic DNA from the tumors and starting pool was extracted. The
representations of the respective shRNA hairpins in the starting pool and
the tumors were determined by high-throughput sequencing (Illumina).
The relative abundance of the individual shRNAs in the starting pool
varied between 2% and 6% of the total population, presumably due to
modest differences in the transduction efficiency of the individual
lentiviral preparations (Supplementary Table 1). The frequency of each
shRNA was compared in the starting pool versus each established tumor.
Cells transduced with non-silencing shRNA (NT-shRNA) constituted
the bulk of the cells of the tumor at the end of the study, while cells
transduced with positive control Aurora B shRNA were almost
undetectable (Figure 1B). The relative abundance of shRNAs targeting
each of the 12 targets queried in the screen was consistent in the
replicate tumors (10-12 tumors per shRNA; Figures 1B and
Supplementary Figure 2). To validate the results from the pooled
shRNA screen, we selected three nutrient transporters, CAIX, MCT4,
and xCT, to confirm their role in tumor growth as implicated previously
[12,17–21].
CAIX, MCT4, and xCT were validated by knockdown using
individual shRNAs in a non-pooled format. PDX15 primary
pancreatic tumor cells were transduced with two separate shRNAs
for each target and implanted separately into RAG2 KOmice. After 3
to 4 weeks, palpable tumors were easily observed in mice implanted
with untreated tumor cells as well as tumor cells transduced with
empty vector lentivirus. In contrast, no tumors were observed in mice
that received cells in which the expression of hits from the pooled
screen was knocked down individually (Table 1).
We focused on CAIX to decipher its role in tumorigenesis because
it is a druggable target, as several CAIX-targeting therapeutic agents
are at different phases of preclinical and clinical development [22],
and because it was the top hit of the pooled shRNA screen (~91%
decrease in prevalence with respect to the starting pool). The decrease
in prevalence of individual shRNAs in a pooled shRNA screen could
be the result of inhibition of either tumor initiation or tumor growth/
maintenance. Recent data implicating CAIX as a driver of breast
cancer “stemness” suggest the former may be relevant [23]. The
relative expression of CAIX in the TIC and bulk tumor cell
populations of the pancreatic 479 PDX model was therefore queried.
In pancreatic cancer, various cell surface proteins have been evaluated
as stem cell markers, including EpCAM, CD44, CD24 [24], CD133
[25], and c-Met [26,27]. In one of the earlier studies, Li et al.
demonstrated that EpCAM+CD44+CD24+ cells could initiate tumors
when as few as 100 cells were injected into immune-deficient mice [24].
We used these markers to isolate TIC and non-TIC populations by
FACS. Flow cytometry analysis indicated high CAIX expression in
TICs (EpCAM+/CD44+/CD24+; Figure 2, A and B). Increased
expression of CAIX was further confirmed by qPCR analysis using total
RNA isolated fromCD44+/CD24+ and CD44−/CD24− populations
(Figure 2C), which suggests differential genetic or epigenetic regulation
of CAIX between TIC and non-TIC cells in vivo.
The increased expression of CAIX in the TICs prompted us to
investigate the role of CAIX in pancreatic PDX15 model tumor
initiation. EpCAM+/CAIX (high) and EpCAM+CAIX (low) cell
populations were isolated using FACS (Figure 3B) and tested for their
tumor initiating capabilities when implanted in varying numbers (5000,
1000, 500, and 100 cells) into RAG2KOmice and grown for 3months.
Four to 6 weeks post-implantation, we saw at least a doubling in the
tumor formation rate for CAIX (high) cells versus CAIX (low) cells at all
levels of tumor cell inoculation (Figure 3A and Table 2). Furthermore,
A B
Figure 1. Schematic design of in vivo pooled shRNA screening strategy to identify novel targets for cancer metabolism. (A) Outline of the
experimental design. (B) Percentage frequency of shRNA hairpins to selected targets present in tumors normalized with respect to the
starting pool (injected cell population).
Table 1. Validation of Selected Genes In Vivo in the RAG2 KO Mouse Model
Summary of Individual shRNA knock down (KD) Data
Treatment Arm Tumor Take Rate
Untreated 6/6
Empty vector (pLKO) 6/8
CAIX-shRNA1 0/8
CAIX-shRNA2 0/8
MCT4-shRNA1 0/8
MCT4-shRNA2 0/8
xCT-shRNA1 0/8
xCT-shRNA2 0/8
Tumor take rate of the primary pancreatic tumor cells (PDX15) expressing shRNAs targeting CAIX
(shRNA1 and shRNA2), xCT (shRNA1 and shRNA2), MCT4 (shRNA1 and shRNA2), empty
vector (pLKO), and untreated control.
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smaller than those initiated fromCAIX (high) cells, indicating that CAIX
may play a dual role in both tumor initiation and tumor proliferation.
To further examine if increased expression of CAIX has any
functional significance in PDX15 tumor formation, we silenced CAIX
expression in EpCAM+/CAIX (high) cells (5000 cells) with two specific
shRNAs and implanted the cells into mice. CAIX silenced cells failed to
initiate tumors, while tumors were observed in animals inoculated with
the cells transduced with NT-shRNA (Figure 4A) or untransduced
control (data not shown). Tumor growth rates of the treatment arms
were followed for 60 days (summarized in Table 3). While a role in
tumor proliferation cannot be ruled out, these results suggest that CAIX
expression is required for the tumor initiating activity of the EpCAM+/
CAIX (high) population.
Discussion
Functional genomic screens using RNA interference have proven
successful for the simultaneous identification and validation of novel
genes involved in tumor progression. However, to date, no such study
has been carried out with a clinically relevant primary tumor model
for the identification of novel targets. Thus, a proof-of-concept study
was carried out in patient-derived pancreatic tumor cells (PDX15).
We simplified the size of the library and chose 12 genes, which were
implicated in tumor metabolism and, consequently, in tumor growth.
Thus, we found that shRNA hairpins for all 12 genes were
differentially depleted in the final tumors. Although the genes chosen
in the screen were reported in the literature to be strongly associated
in tumorigenesis, we found great differences in representation
(depletion frequency) of the 12 genes in the context of primary
pancreatic tumor growth (PDX15). Thereafter, we focused on those
targets that showed the highest and most consistent depletion of both
the shRNA hairpins in the final tumors. Thus, 8 of the 12 shRNA
pairs display less than b15% differences in percent inhibition oftumor growth (Pb0.05). On a different note, we saw substantial
variations in depletion frequencies of certain shRNA hairpins
targeting the same gene (SGLT1, Glut1, ZIP4, and ASCT2;
P b 0.05). Although, these shRNAs were prevalidated by in vitro
knockdown assays, such results are not well understood. Plausible
reasons for above results could be the altered stability and/or silencing
efficiency of shRNA hairpins under in vivo environment. However,
understanding the mechanisms of such outcome is beyond the scope
of the current paper. In brief, our results demonstrate that PDX
model could be a feasible tool for carrying out shRNA loss of function
screen. Therefore, future shRNA screens could be carried out in PDX
models derived from pancreatic and other indications.
xCT, a cysteine/glutamate anti-porter that imports cysteine (the
dimeric form of cysteine), is one of three amino acids required for
glutathione synthesis. Detoxification of toxic compounds and
amelioration of oxidative stress in tumor cells are critically dependent
on this antioxidant. Due to this requirement, xCT is overexpressed in
pancreatic and triple-negative breast cancer [28,29]. Previous reports
indicate that forced reduction of xCT levels reduces viability of cancer
AC
B
Figure 2. Increased expression of CAIX in primary pancreatic (PDX15) TICs versus non-TICs. (A) Assessment of CAIX cell surface levels in
tumor initiating (EpCAM+/CD44+/CD24+) and non-tumor initiating (EpCAM+/CD44−/CD24−) populations. (B) Graphical represen-
tation of A. The graph describes median fluorescence of TIC and non-TIC populations. (C) Relative mRNA expression of TIC and non-TIC
populations by TaqMan analysis.
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peutics [29], and our results importantly extend these observations to
a pancreatic PDX model. These results are significant because they
suggest that some tumors are exclusively reliant on xCT to provide
cysteine for glutathione synthesis and do not leverage other
potentially redundant pathways as described earlier [31]. Increased
reliance on xCT for import of cysteine for glutathione synthesis also
suggests that targeting of this receptor will provide greater therapeutic
margins than direct inhibition of glutathione synthesis that would be
expected to result in wide-ranging toxicities [32]. Thus, xCT is
considered an attractive target for cancer [28,29].
Activation of oncogenes reprogram cancer cells toward aerobic
glycolysis to support their proliferation and growth, a phenomenon
known as the Warburg effect [2]. Aerobic glycolysis is a fast route for
production of ATP and other precursors required for synthesis of
nucleotides, proteins, and lipids. Addiction of cancer cells to aerobic
glycolysis therefore leads to accumulation of lactic acid. To maintain
pH homeostasis, cells export lactic acid to prevent cellular
acidification. MCT4 is one of four members of the solute carrier
family 16A with symport H+ and lactate anions across the plasma
membrane. Two of these members (MCT1 and MCT4) are mainly
responsible for the efflux in cancer cells. As a result, elevated levels of
MCT1 and MCT4 are characteristic of solid tumors and often
associated with poor prognosis [33–36]. In particular, high MCT4
expression has been reported in renal, prostate, pancreatic, andcervical cancers [34,37,38]. Several studies have further confirmed
that silencing of MCT1 or MCT4 function significantly suppressed
tumor growth in in vivo and in vitro models [7,38,39]. Thus, our
data strongly corroborate these findings and suggest that MCT4 is
required for primary pancreatic tumor (PDX15) growth.
CAIX was the top hit of the pooled shRNA screen. Hypoxia is a
hallmark of many solid tumors, and CAIX is considered to be a marker
for a hypoxic microenvironment. The regulation of CAIX by
hypoxia-inducible transcription factor 1 and the role of CAIX in the
regulation of pH dynamics in solid tumors are well characterized [22].
CAIX maintains pH homeostasis in cells and protects from the
deleterious effects of acidosis caused by the high rate of aerobic glycolysis
in tumors [22]. CAIX is an extracellular membrane-bound enzyme that
catalyzes a hydration reaction that converts carbon dioxide to
bicarbonate. Bicarbonate, in turn, is imported through specific
transporters and promotes cell survival through buffering of intracellular
pH [12]. In addition to its role in the regulation of tumoral pH and cell
survival, there is evidence that suggests that CAIX is also involved in cell
adhesion, migration, and metastasis [17]. Furthermore, silencing of
CAIX expression in 4T1mouse metastatic breast cancer cells resulted in
regression of orthotopic mammary tumors and inhibition of
spontaneous lung metastasis [18]. Likewise, stable depletion of CAIX
in MDA-MB-231 human breast cancer xenografts also attenuated
primary tumor growth [18]. Our results corroborate these findings and
indicate that CAIX is an attractive target for cancer.
A B
Figure 3. Increased tumor initiating potential of CAIX-enriched primary pancreatic tumor cells (PDX15). EpCAM+CAIX+ and
EpCAM+CAIX− sorted cells from PDX15 tumors were implanted at indicated numbers in RAG2 KO mice. (A) Growth curve of
EpCAM+CAIX+ and EpCAM+CAIX− phenotypes in RAG2 KO mice. Mice were implanted with 5000 cells of each population and were
euthanized when tumor volume reached~2000mm3. (B) The gating strategy used to sort cells representing CAIX(+) or CAIX(−) phenotype.
A
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characteristics including low mitochondrial respiration and increased
glycolysis for ATP generation [40]. TICs also prefer a hypoxic niche
to maintain their “stemness” and tumor initiating potential
[23,41,42]. These observations led us to evaluate expression of
CAIX in the TIC and non-TIC populations of a pancreatic tumor
model. CAIX is significantly overexpressed in TICs compared to
non-TICs as confirmed by flow cytometry and qPCR analysis.
Consistent with these observations, “stemness” markers, such as Oct4
and Nanog, and Epithelial mesenchymal transition (EMT) markers,
like Snail and Twist, are also substantially overexpressed in
CAIX-bearing TICs (data not shown). Additionally, our data
demonstrate that CAIX-enriched epithelial cells (EpCAM+) of
PDX15 display robust tumor initiation potential. As low as 100
cells (EpCAM+/CAIX+) were able to initiate palpable tumors in
RAG2 KO mice. Recent data suggest that CAIX expression is
required for the expression of EMT markers and may be involved in
maintaining EMT status in breast cancer stem cells [23]. Our findings
strongly corroborate the notion that cancer stem cells prefer a hypoxic
niche to maintain their pluripotent potential and that CAIX plays an
important role in survival in this metabolically altered, harsh
microenvironment. Additionally, it is imperative to explore the
abundance of CAIX expression in TICs of other solid tumors such as
brain, colon, and head and neck, which often have a hypoxic
microenvironment due to rapid cell division and aberrant blood vessel
formation [43,44].
Genes identified as hits in an shRNA screen are predicted to be
essential for autocrine growth pathways, while genes driving paracrineTable 2. Summary of the Tumor Take Rate of EpCAM+/CAIX+ Cells
Cells
Inoculated
Tumor Incidence Comments
CAIX(+) CAIX(−)
100 2(3) 1(3) Ep+CAIX− tumors ~4 times smaller than Ep+CAIX+ tumors
500 7(8) 1(8) Ep+CAIX− tumors ~4 times smaller than Ep+CAIX+ tumors
1000 6(10) 3(10) Ep+CAIX− tumors ~6 times smaller than Ep+CAIX+ tumors
5000 4(4) 2(4) Ep+CAIX− tumors ~8 times smaller than Ep+CAIX+ tumors
Take rate of CAIX+ and CAIX− populations in mice inoculated at the indicated cell numbers. For
tumor incidence, the first number represents quantity of mice in which tumor grew, and the second
number in parentheses represents the total number of mice inoculated.growth are predicted to not be represented among the hits since the
effects of their knockdown should be compensated for by the many
neighboring cells knocked down in unrelated pathways and wild type
for the paracrine pathway of interest. CAIX is predicted to be a
paracrine actor since the bicarbonate produced by one cell should be
available for import by neighboring cells. The fact that CAIX was
detected in an autocrine pathway–focused shRNA screen suggests
that it may have additional functions beyond CO2 hydration. One
plausible CO2-independent mechanism of action could be through
p21 pathway regulation since this important cell cycle progression
inhibitor has been shown to be upregulated following CAIX silencing
[45]. Furthermore, it appears that loss of CAIX expression activates
β1 integrin pathways that may influence the proliferation of TICs.
Thus, we hypothesize that the increased expression of CAIX may
influence the survival and proliferation of TICs by the following two
modalities: 1) by modulation of signaling pathways such as those
involving p21 or β1 integrin and 2) by regulation of extracellular pH
(extrinsic factors), thus allowing TICs to thrive in a hypoxic and
acidic microenvironment. Future experiments will compare theFigure 4. Silencing of CAIX expression by shRNAs significantly
reduces tumor forming potential of PDX15. (A) Growth characteris-
tics of CAIX-enriched EpCAM+ cells (5000 cells per mouse) that
were transduced with either CAIX shRNAs (shRNA1 or shRNA2) or
NT-shRNA.
Table 3. Tumors Take Rates of Transduced CAIX+ Populations. Number of Mice with
Established Tumors 60 Days Following Inoculation with CAIX+ PDX15 Tumor Cells with or
without CAIX Knockdown
Treatment Arm Tumor Take Rate
NT-shRNA 5/5
CAIX-shRNA1 1/5
CAIX-shRNA2 0/5
Neoplasia Vol. 17, No. 6, 2015 In vivo Loss of Function Screening Pore et al. 479ability of wild-type and catalytically inactive CAIX to rescue the
effects of shRNA knockdown.
Since the introduction of the TIC concept, huge efforts have been
invested to identify and characterize markers specific to TICs. As a
consequence, overwhelming and steadily increasing numbers of such
markers have been described [46,47]. To date, however, the function of
suchmarkers in TICs is still not fully understood. Our data suggest that
CAIX is highly overexpressed in pancreatic TICs and could be used as a
marker to identify and characterize these cells. Likewise, the expression
of the other hits obtained from our shRNA screen could be further
investigated to explore their requirement in TICs. Such efforts could
identify novel markers or targets for TICs across various cancer types.
Overall, our data indicate that pooled shRNA screens in PDXmodels
are a viable path for target discovery. We took an unbiased approach to
successfully identify novel targets using bulk populations of PDX15.
The design of the experiment was such that targets for both tumor
initiation and tumor proliferation would be identified. Similar
approaches could be exploited to identify novel targets from the
TIC-enriched population but are beyond the scope of the current paper.
On the whole, our data indicate that inhibition of CAIX function may
block both tumor initiation and proliferation. We propose that blocking
of CAIX function with specific inhibitors and in combination with
clinically approved or validated targeted therapies may lead to successful
strategies to prevent tumor growth and metastasis in solid tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.05.001.
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